Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Retevmo (selpercatinib) capsules Right
  4. RETEVMO® (selpercatinib): Dosing Considerations
Search Retevmo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Retevmo ® (selpercatinib) capsules

40 mg, 80 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

RETEVMO® (selpercatinib): Dosing Considerations

Selpercatinib may be taken with or without food unless coadministered with a proton pump inhibitor.

US_cFAQ_SEL300-X2_DOSING_CONSIDERATIONS
US_cFAQ_SEL300-X2_DOSING_CONSIDERATIONS
en-US

Detailed Information

  • Selpercatinib doses should be separated by approximately 12 hours.
  • A missed dose of selpercatinib should not be made up within 6 hours of the next scheduled dose.
  • Selpercatinib capsules should be swallowed whole and should not be opened, crushed, or chewed.1
    • Lilly currently has no information available on the opening of the capsules and administering the content in liquids or food for administration (such as mixing in applesauce) or administration through a G-tube.
  • If vomiting occurs after taking a dose of selpercatinib, do not administer an additional dose. Take the next dose at the scheduled time.1

Selpercatinib is taken orally twice daily until disease progression or unacceptable toxicity. The recommended dose of selpercatinib based on actual body weight is detailed in Recommended Selpercatinib Dosage.1

Recommended Selpercatinib Dosage1

Patient Weighta

Recommended Dosage

<50 kg

120 mg orally twice daily

≥50 kg

160 mg orally twice daily

aBased on actual patient weight.

Enclosed Prescribing Information

RETEVMO® (selpercatinib) capsules, for oral use, Lilly

Reference

1Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Glossary

G-tube = gastrostomy tube

Lilly = Eli Lilly and Company

Date of Last Review: January 04, 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly